BRIEF-MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax

Reuters03-26

March 26 (Reuters) - MEI Pharma Inc :

* MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA

* MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY

* MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1

* MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment